Moreover, LCN2 has been linked to acquired resistance to almonertinib in non-small cell lung cancer (NSCLC) through the LCN2-MMP-9 signaling pathway and its regulation by HNRNPA2B1-mediated mA modification of FOXM1 facilitates Cisplatin (DDP) resistance and inhibits ferroptosis in endometrial cancer cells (131, 132). The gene discussed is LCN2; the disease is non-small cell lung carcinoma.